[go: up one dir, main page]

WO1998022499A3 - Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof - Google Patents

Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof Download PDF

Info

Publication number
WO1998022499A3
WO1998022499A3 PCT/CA1997/000868 CA9700868W WO9822499A3 WO 1998022499 A3 WO1998022499 A3 WO 1998022499A3 CA 9700868 W CA9700868 W CA 9700868W WO 9822499 A3 WO9822499 A3 WO 9822499A3
Authority
WO
WIPO (PCT)
Prior art keywords
arretin
receptors
fragments
nucleic acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1997/000868
Other languages
French (fr)
Other versions
WO1998022499A2 (en
WO1998022499A9 (en
Inventor
Lisa Joan Mckerracher
Samuel David
Peter Erich Braun
Zhi-Cheng Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU50442/98A priority Critical patent/AU5044298A/en
Publication of WO1998022499A2 publication Critical patent/WO1998022499A2/en
Publication of WO1998022499A3 publication Critical patent/WO1998022499A3/en
Publication of WO1998022499A9 publication Critical patent/WO1998022499A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a neuron and neural tumor growth regulatory system, based on the novel protein, arretin and its isoforms and fragments thereof, its receptor, antibodies directed against the components of this system and diagnostic, therapeutic, and research uses for each of these aspects. This protein has an apparent molecular weight of approximately 70 kDa. Embodiments of the invention comprise the amino acid sequence and probes designed therefrom for nucleic acid sequences encoding arretin. Alternatively, tagged arretin protein for use as a reporter to detect receptors of arretin, which are then sequenced and used to obtain probes for the nucleic acid sequences encoding arretin receptors, are included. The present invenetion further relates to arretin receptors and fragments thereof as well as the nucleic acid sequences coding for such arretin receptors and fragments, and their therapeutic and diagnostic uses. Substances which function as either aganists or antagonists to arretin receptors are also envisioned and included within the scope of the present invention.
PCT/CA1997/000868 1996-11-15 1997-11-17 Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof Ceased WO1998022499A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50442/98A AU5044298A (en) 1996-11-15 1997-11-17 Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,190,418 1996-11-15
CA 2190418 CA2190418A1 (en) 1996-11-15 1996-11-15 Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof

Publications (3)

Publication Number Publication Date
WO1998022499A2 WO1998022499A2 (en) 1998-05-28
WO1998022499A3 true WO1998022499A3 (en) 1998-07-30
WO1998022499A9 WO1998022499A9 (en) 1998-09-11

Family

ID=4159259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000868 Ceased WO1998022499A2 (en) 1996-11-15 1997-11-17 Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof

Country Status (3)

Country Link
AU (1) AU5044298A (en)
CA (1) CA2190418A1 (en)
WO (1) WO1998022499A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
WO2006111348A1 (en) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003601A2 (en) * 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
WO1994017831A1 (en) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
WO1995020397A1 (en) * 1994-01-27 1995-08-03 New York University Phosphacan, nucleic acids encoding thereof and antibodies thereto
WO1995022344A1 (en) * 1994-02-21 1995-08-24 Mcgill University Therapeutic use of myelin-associated glycoprotein (mag)
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
WO1996032476A1 (en) * 1995-04-13 1996-10-17 Mount Sinai Hospital Corporation Modulator of neuronal cell response to inhibition by cns myelin
WO1996032959A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003601A2 (en) * 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
WO1994017831A1 (en) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
WO1995020397A1 (en) * 1994-01-27 1995-08-03 New York University Phosphacan, nucleic acids encoding thereof and antibodies thereto
WO1995022344A1 (en) * 1994-02-21 1995-08-24 Mcgill University Therapeutic use of myelin-associated glycoprotein (mag)
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
WO1996032476A1 (en) * 1995-04-13 1996-10-17 Mount Sinai Hospital Corporation Modulator of neuronal cell response to inhibition by cns myelin
WO1996032959A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BODE-LESNIEWSKA ET AL.: "Distribution of the large aggregating proteoglycan versican in adult human tissues", THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 44, no. 4, - April 1996 (1996-04-01), pages 303 - 312, XP002062505 *
ESKO J.: "GENETIC ANALYSIS OF PROTEOGLYCAN STRUCTURE, FUNCTION AND METABOLISM", CURRENT OPINION IN CELL BIOLOGY, vol. 3, 1991, pages 805 - 816, XP002062506 *
FRIEDLANDER ET AL.: "THE NEURONAL CHONDROITIN SULFATE PROTEOGLYCAN NEUROCAN BINDS TO THE NEURAL CELL ADHESION MOLECULES Ng-CAM/L1/NILE AND N-CAM, AND INHIBITS NEURONAL ADHESION AND NEURITE OUTGROWTH", THE JOURNAL OF CELL BIOLOGY, vol. 125, no. 3, 1994, pages 669 - 680, XP002062504 *
SCHWAB M E ET AL: "INHIBITORS OF NEURITE GROWTH", ANNUAL REVIEW OF NEUROSCIENCE, vol. 16, 1 January 1993 (1993-01-01), pages 565 - 595, XP000576555 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012930B2 (en) 1999-12-17 2011-09-06 Curemark, Llc Methods of treating pervasive development disorders
US8105584B2 (en) 1999-12-17 2012-01-31 Curemark Llc Method for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US8613918B2 (en) 1999-12-17 2013-12-24 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8486390B2 (en) 2008-04-18 2013-07-16 Curemark Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US12485094B2 (en) 2020-09-10 2025-12-02 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
WO1998022499A2 (en) 1998-05-28
CA2190418A1 (en) 1998-05-15
AU5044298A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
WO1998022499A3 (en) Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998031806A3 (en) Fc receptors and polypeptides
DK0939804T3 (en) Neutrokine-alpha
WO2001055448A8 (en) Nucleic acids, proteins, and antibodies
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
WO2001054472A8 (en) Nucleic acids, proteins, and antibodies
CA2174971A1 (en) Neural Axon Outgrowth Modulators
WO2000020447A8 (en) Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
WO1998011234A3 (en) Human protein kinases
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
WO2000061774A3 (en) Bone morphogenic proteins
EP1212340A4 (en) 29 human cancer associated proteins
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
WO2000065054A3 (en) Human membrane-associated proteins
WO2005003299A3 (en) Polynucleotides encoding novel guanylate binding proteins (gbp's)
DE69634994D1 (en) BOND WEAVE GROWTH FACTOR 3.
WO2002030979A3 (en) Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
KR950003312A (en) Chondrocyte protein
WO2001046256A3 (en) Vesicle trafficking proteins
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/14-6/14 AND 10/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-6/14 AND 10/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA